In vitro efficacy of diclofenac against Listeria monocytogenes

Cited 15 time in Web of Science Cited 18 time in Scopus

Dutta, N. K.; Mazumdar, K.; Baek, M. W.; Kim, D. J.; Na, Y. R.; Park, S. H.; Lee, H. K.; Lee, B. H.; Park, Jae Hak

Issue Date
Springer Verlag
Eur J Clin Microbiol Infect Dis 27(4):315-319
Chemotherapy is often futile in systemic listeriosis, translating to being a peril to public health. There is, thus, an imperative need for novel antilisterial compounds, possibly acting through mechanisms dissimilar to those of existing drugs. The present study describes one such agent—the non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium (Dc). The National Committee for Clinical Laboratory Standards (NCCLS) minimum inhibitory concentration (MIC), mode of action, and two mechanisms of action, i.e., on bacterial DNA and membrane, have been characterized with respect to Dc. The drug showed noteworthy inhibitory action (MIC90 = 50 μg/ml) against Listeria strains, demonstrated cidal (minimum bactericidal concentration [MBC]=100 μg/ml) activity, inhibited listerial DNA synthesis (45.48%; incorporation of [methyl-3H] thymidine), and possessed bacterial membrane-damaging activity (37.33%; BacLight assay). Dc could be used as a lead compound for the synthesis of new, more active agents perhaps devoid of side effects. Further, quantitative structure–activity relationship (QSAR) studies will contribute to a new generation of promising adjuvants to existing antilisterial drugs.
0934-9723 (print)
1435-4373 (online)
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Veterinary Medicine (수의과대학)Dept. of Veterinary Medicine (수의학과)Journal Papers (저널논문_수의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.